STIC-ILL

NO

From: Canella, Karen
Sent: Monday, September 23, 2002 4:50 PM
To: STIC-ILL
Subject: ill order 09/673,686

4/13819

\rt Unit 1642 Location 8E12(mail)

Telephone Number 308-8362

Application Number 09/673,686

1. BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 1995:456482 BIOSIS
DOCUMENT NUMBER: PREV199598470782
TITLE: Delayed-type hypersensitivity reaction in the skin with autologous modified lymphocytes in lung cancer patients.
AUTHOR(S): Ageenko, A. I. (1); Erkhov, V. S.; Bakhlaev, I. E.; Oleinik, E. K.; Trakhtenberg, A. Kh.
CORPORATE SOURCE: (1) P.A. Herzen Mosc. Oncol. Res. Inst., Russ. Minist. Health Med. Ind., Moscow 125284 Russia
SOURCE: Eksperimental'naya Onkologiya, (1994) Vol. 16, No. 4-6, pp. 367-370.
ISSN: 0204-3564.
DOCUMENT TYPE: Article
LANGUAGE: Russian
SUMMARY LANGUAGE: Russian; English

2. MEDLINE DUPLICATE 3
ACCESSION NUMBER: 95334993 MEDLINE
DOCUMENT NUMBER: 95334993 PubMed ID: 7610621
TITLE: [Delayed-type hypersensitivity skin test with modified autologous lymphocytes in the diagnosis and monitoring of patients with lung cancer]. Kozhnaia reaktsiia GZT s autologichnymi modifitsirovannymi limfotsitami v diagnostike i monitoringe bol'nykh rakom legkogo.
AUTHOR: Bakhlaev I E; Erkhov V S; Ageenko A I; Oleinik E K; Trakhtenberg A K
SOURCE: VOPROSY ONKOLOGII, (1994) 40 (7-12) 284-8.
Journal code: 0413775. ISSN: 0507-3758.
PUB. COUNTRY: RUSSIA: Russian Federation
DOCUMENT TYPE: (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: Russian
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199508
ENTRY DATE: Entered STN: 19950828
Last Updated on STN: 19950828
Entered Medline: 19950811

LOL — NO
stat 9/27
CAT 9/30

3. MEDLINE DUPLICATE 4
ACCESSION NUMBER: 93127589 MEDLINE
DOCUMENT NUMBER: 93127589 PubMed ID: 1843160
TITLE: [The nature of the immunological tumor -host interrelationships]. K voprosu o prirode immunologicheskikh vazimootnoshenii opukhol'--organizm.
AUTHOR: Erkhov V S; Ageenko A I
SOURCE: VOPROSY ONKOLOGII, (1991) 37 (6) 751-4.
Journal code: 0413775. ISSN: 0507-3758.
PUB. COUNTRY: RUSSIA: Russian Federation
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

STIC-FPAS

From: Canella, Karen
Sent: Monday, September 23, 2002 4:35 PM
To: STIC-FPAS
Subject: english language equivalents

Art Unit 1642 Location 8E12(mail)

Telephone Number 308-8362

Application Number 09/673,686

I would like english languguage equivalents for any of the following (ASAP, please, if possible):

1990 1. ~~SU 1589215 A1~~ ✓
2. ~~SU 1649443 A1~~
3. ~~SU 1709220 A1~~
1993 4. SU 1805392 A1 ✓ 1993
1992 5. SU 1704087 A1 ✓ 1992
1993 6. SU 1836640 A1 ✓
7. ~~RU 2063768 C1~~
1997 8. RU 2077725 C1 ✓ 1998
9. RU 2025734 C1 CA 2023030 US 5459035 (1995)
10. ~~RU 2137136 C1~~
1997 11. WO 9722881 A1 ✓ (1997)

Thanks

priority doc !?

EP 465 715 1992

COMPLETED

2/34/11 **(Item 11 from file: 345)**
9454072
Basic Patent (No,Kind,Date): SU 1589215 A1 900830

PATENT FAMILY:
UNION OF THE SOVIET SOCIALIST REPUBLICS (SU)
Patent (No,Kind,Date): SU 1589215 A1 900830
METHOD OF PREDICTING RECURRENCIES OF ACUTE LYMPHOBLASTIC LEUKOSIS (English)
Patent Assignee: TSNII GEMATOLOGII PERELIVANIYA (SU)
Author (Inventor): MITEREV GEORGIJ YU (SU); NOVIKOVA MARINA S (SU); BULYCHEVA TATYANA I (SU); ABAKUMOV EVGENIJ M (SU); ISAEV VALENTIN G (SU); MOROZOVA NINA G (SU)
Priority (No,Kind,Date): SU 4311926 A 870930
Applic (No,Kind,Date): SU 4311926 A 870930
IPC: * G01N-033/53
Derwent WPI Acc No: ; C 91-221019
Language of Document: Russian

2/34/12 (Item 1 from file: 351)

013257187
WPI Acc No: 2000-429070/ **200037**
Method of diagnosing malignant tumors utilizing common tumor antigen-specific antiserum
Patent Assignee: ERKHOV V S (ERKH-I)
Inventor: ERKHOV V S
Number of Countries: 001 Number of Patents: 001
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week	
RU 2137136	C1	19990910	RU 98103027	A	19980227	200037	B

Priority Applications (No Type Date): RU 98103027 A 19980227
Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
RU 2137136	C1			G01N-033/53	

Abstract (Basic): **RU 2137136** C1

NOVELTY - Embryo in Letus stage is isolated from genetically alike rats and cell suspension is prepared. From immunized animals, spleen cells are taken off to isolate lymphocytes and prepare lymphocyte suspension. Animal of the same genetic line is subjected to second immunization step with above lymphocyte suspension. Thereafter, antiserum is obtained, supplemented by cells of intact organs of the same animals and mixture is decanted. Supernatant is filtered through millipore filter with pore diameter 20 mcm. Filtrate is added to test animal blood for measuring immunofluorescence and erythrocyte sedimentation rate. When measured values are reliably differ from control values, tumor ids diagnosed.

USE - Oncology.

ADVANTAGE - Increased sensitivity and specificity of diagnostics.

pp; 0 DwgNo 0/0
Derwent Class: B04; S03
International Patent Class (Main): G01N-033/53
International Patent Class (Additional): G01N-033/96

2/34/13 (Item 2 from file: 351)

011632944
WPI Acc No: 1998-050072/ **199805**
Detection of cancer-embryo antigen - using diagnostic medium containing antibodies to cancer-embryo antigen bound with erythrocytes of hens treated with glutaraldehyde
Patent Assignee: SOLSKAYA L L (SOLS-I)
Inventor: MURATKHODZHAEV N K; PRUS E S; RASHIDOVA R A
Number of Countries: 001 Number of Patents: 001
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week	
RU 2077725	C1	19970420	SU 5030789	A	19920305	199805	B

Priority Applications (No Type Date): SU 5030789 A 19920305
Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
RU 2077725	C1		7	G01N-033/53	

Abstract (Basic): RU 2077725 C

Detection of cancer-embryo antigen is based on use of special antibody-type diagnostic medium and comprises mixing blood sample with such medium, containing specific antibodies to cancer-embryo antigen (CEA) bound with erythrocytes of 1- and 2 years old hens treated with glutaraldehyde, with subsequent recording of reaction of haemagglutination of antigen with antibody.

Antibody-erythrocyte diagnostic medium is prepared by treating erythrocytes separated from blood of 1-2 years old hens with glutaric aldehyde, and combining them with anti-(CEA) antibodies. A sample of blood serum of a patient is then mixed with the diagnostic medium, with subsequent recording of titre of AGA reaction signalling presence of antigen. For healthy patients this titre should not be > 1:4, and the titre from 1:8 to 1:64 indicates malignant tumour.

USE - The method is used in medicine and immunological analysis as a method of early detection of tumours - producers of cancer-embryo antigen. The antigen can be present in blood of a healthy patient in amount 0-20 ng/ml, but increase of its concentration above 40 ng/ml indicates the presence of malignant tumour.

ADVANTAGE - The method uses cheap and widely available material for preparation of diagnostic medium.

Dwg.0/0

Derwent Class: B04; D16; S03
International Patent Class (Main): G01N-033/53

2/34/14 (Item 3 from file: 351)

011363926
WPI Acc No: 1997-341833/ **199731**
Diagnosis of malignant tumours - is based on erythrocyte sedimentation rates
Patent Assignee: ERKHOV V S (ERKH-I); AGEENKO A I (AGEE-I)
Inventor: AGEENKO A I; ERKHOV V S
Number of Countries: 065 Number of Patents: 003
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week	
WO 9722881	A1	19970626	WO 96RU3	A	19960103	199731	B
AU 9644030	A	19970714	AU 9644030	A	19960103	199744	
RU 2111495	C1	19980520	RU 95120436	A	19951215	199850	

Priority Applications (No Type Date): RU 95120436 A 19951215
Cited Patents: EP 232706; EP 58616; FR 2482309; SU 1176886
Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
WO 9722881	A1	R	11	G01N-033/80	

Designated States (National): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO SD SE SG SI SK TJ TM TT UA UG US UZ VN
Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG

AU 9644030	A	G01N-033/80	Based on patent WO 9722881
RU 2111495	C1	G01N-033/80	

Abstract (Basic): WO 9722881 A

Diagnosis malignant tumours comprises: (1) measuring the erythrocyte sedimentation rate (ESR) in the presence of: (a) an anti-idiotypic antiembryonic serum from rats immunised with lymphocytes from intact syngeneic animals, and (b) a control rat serum; (2) calculating a malignancy growth coefficient (MGC), and (3) diagnosing malignant growth if the MGC is 1.55-7.0.

The MGC is calculated from the formula MGC = ((Cmax-Cmin) multiply 2Cmax) divided by 100, where Cmax is the maximum ESR and Cmin is the minimum ESR.

ADVANTAGE - The method is universally applicable, being independent of the degree of tumour localisation and the stage of disease progression.

Dwg.0/0

Derwent Class: B04; D16; S03
International Patent Class (Main): G01N-033/80

2/34/15 (Item 4 from file: 351)

011165879
WPI Acc No: 1997-143804/ **199713**
Prepn. of antigen(s) from tumour tissues - by drying frozen and chopped tissue then extracting with distilled water in presence of merthiolate
Patent Assignee: FIGURNOV V A (FIGU-I)
Inventor: FIGURNOV V A
Number of Countries: 001 Number of Patents: 001
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week	
RU 2063768	C1	19960720	SU 5007276	A	19910814	199713	B

Priority Applications (No Type Date): SU 5007276 A 19910814
Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
RU 2063768	C1		2	A61K-039/395	

Abstract (Basic): RU 2063768 C

Antigens of cancerous tumours are obtd from tumour tissues of patients who died of cancer as follows. The tissue is frozen, chopped into small 2-4 mm pieces, dried at 35-40 deg. for 32-48 hours, and the antigens extracted with distilled water at 5-7 deg. C in the presence of merthiolate used at 1:10000 dilution to prevent microbial contamination.

USE - Used in immunology.

ADVANTAGE - The method is simpler and the dried tumour tissues can be stored for at least 14-16 months without loss of antigen properties.

Dwg.0/0
Derwent Class: B04
International Patent Class (Main): A61K-039/395

2/34/16 (Item 5 from file: 351)

010236550
WPI Acc No: 1995-137807/ **199518**
Tumour diagnosis - with addn. of an anti-idiotypical, anti-embryonic serum to a whole blood sample and measurement of the erythrocyte deposition rate
Patent Assignee: ERKHOV V S (ERKH-I)
Inventor: AGEENKO A I; ERKHOV V S
Number of Countries: 001 Number of Patents: 001
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week	
SU 1836640	A3	19930823	SU 5048135	A	19920617	199518	B

Priority Applications (No Type Date): SU 5048135 A 19920617
Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
SU 1836640	A3		3	G01N-033/80	

Abstract (Basic): SU 1836640 A

Tumour diagnosis by serological study of the blood is new. An antiidiotypical, antiembryonic serum is added to a sample of the patient's whole blood, the rate of deposition of the patient's erythrocytes (EDR) is measured in the sample and in the control, the difference between these is calculated, multiplied by the max. of both values of the (EDR), and is divided by 50. If the value of the criterion obtd. is higher than 1.5, tumoural growth is diagnosed.

ADVANTAGE - The method is more sensitive and specific than previous methods, and is also more universal, i.e. it can be used for tumour diagnosis irrespective of the special features of their histogenesis and localisation.

Dwg.0/0

Derwent Class: B04; S03
International Patent Class (Main): G01N-033/80

2/34/17 (Item 6 from file: 351)

009914243
WPI Acc No: 1994-181953/ **199422**
Identification of oesophageal cancer risk groups - by using presence of HLA B-35 antigen in lymphocyte antigen compsn. as criterion

Patent Assignee: HAEMATOLOGY BLOOD TRANSFUSION RES INST (HAEM-R); LENGD DOCTORS TRAINING INST (LEDO-R); ONCOLOGY RES INST (ONCO-R)
Inventor: POVGALYUK A R; SEMLUTSKAYA I B; STOLYAROV V
Number of Countries: 001 Number of Patents: 001
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week	
SU 1805392	A1	19930330	SU 4685572	A	19890425	199422	B

Priority Applications (No Type Date): SU 4685572 A 19890425
Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
SU 1805392	A1		6	G01N-033/53	

Abstract (Basic): SU 1805392 A

Lymphocytes are sepd. from defibrinated blood using density gradient centrifugation. Their antigen compsn. is then determined by means of the standard test involving antiserums to the 23 antigens of the HLA system. Tests on 109 patients aged 40-75 suffering from cancer of the oesophagus showed that the frequency with which the HLA B-35 antigen occurred measured 32%, compared to a frequency of 12.3% among healthy people. Further analysis of HLA B-35 antigen occurrence frequency in relation to age, sex, profession and hereditary factors revealed that the group most at risk from the disease comprises men over 40, who have a history of cancer in the family or who work under adverse industrial conditions. The presence of HLA-A19, B5 and B40 antigens was found to coincide with a resistance to the development of oesophageal cancer.

USE/ADVANTAGE - Used in oncology and immunology, for isolating oesophageal cancer risk groups. Greater accuracy is achieved in identifying likely sufferers.

Dwg.0/0

Derwent Class: B04; D16; S03
International Patent Class (Main): G01N-033/53

2/34/18 (Item 7 from file: 351)

009295295
WPI Acc No: 1992-422705/ **199251**
Auto-immune process determn. - divides biopsy sample into two and demonstrates myelin fibre damage accompanied by lympho-monoplasmocyte and lymphocyte infiltrates
Patent Assignee: A MED EXP MEDICINE RES INST (AMEX-R)
Inventor: CHUMASOV E I; KHIZHNYAK M G; SVETIKOVA K M
Number of Countries: 001 Number of Patents: 001
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week	
SU 1709220	A1	19920130	SU 4697357	A	19890414	199251	B

Priority Applications (No Type Date): SU 4697357 A 19890414
Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
SU 1709220	A1		3	G01N-033/53	

Abstract (Basic): SU 1709220 A

The method takes a biopsy sample from a patient and reveals the destruction of the myelin fibres accompanied by lymphomonoplasmacyte and/or lymphomonocyte infiltrates thus allowing the assesment of the autoimmune demyelinisation process.

USE/ADVANTAGE - Applied in establishments dealing with nervous diseases, pathological anatomical work and forensic medicine to determine autoimmune demyelinisation in the living patient.

In an example, a biopsy sample is taken from a patients skin. Two histological sections are prepd. from the latter. One of the sections was stained with sudan black and the other was impregnated with silver, and counter stained with the usual colourants to reveal the deg. of myelin fibre destruction. Bul.4/30.1.92

Dwg.0/0

Derwent Class: B04; S03
International Patent Class (Main): G01N-033/53

2/34/19 (Item 8 from file: 351)

009252888
WPI Acc No: 1992-380305/ **199246**
Diagnosing retino-blastoma in children - by determn. of migration capability of peripheral blood leucocytes, using water-soluble antigen prepn. made of retino-blastoma biopsy material
Patent Assignee: PHYS CHEM MEDICINE RES INST (PHYS-R)
Inventor: KARGINA I B; KHVATOVA A V; SKRYABINA O A
Number of Countries: 001 Number of Patents: 001
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week	
SU 1704087	A1	19920107	SU 4716767	A	19890710	199246	B

Priority Applications (No Type Date): SU 4716767 A 19890710
Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
SU 1704087	A1		4	G01N-033/53	

Abstract (Basic): SU 1704087 A

The method is based on an immunological reaction of a patient to an aq.-salt extract of retinoblastoma cells obtd. by biopsy, and comprises determn. of migration capability of leucocytes in peripheral blood of the patient in contact with a water-soluble antigen prepn. made of biopsy material and contg. polypeptides of m.wt. 50-100 kD, in concn. 100-200 micro g/ml per 2.5x10 power 5 leucocytes.

Index of migration of leucocytes (MI) is calculated using an expression: (MI)=Ia/Ikx100%, wherre Ia is the average width of migration zone in leucocyte samples contg. the antigen prepn. and Ik is the average width of migration zone for control samples (both measured after 17 hrs. from the start of analysis). The level of migration index below 95% indicates retinoblastoma while the index equal 95% and higher indicates non-tumour pathology.

The method has high specificity and reproducibility and gives differential diagnosis between retinoblastoma and non-tumour pathology, as well as accurate diagnosis of early (I-II) and late (III-IV) stages of retinoblastoma, and detection of tumour in second eye after surgical removal of first.

USE/ADVANTAGE - In medicine, esp. onco-opthalmology, as a method of differential diagnosis of retinoblastoma and non-tumour eye pathology. The method is simple, non-traumatic and offers high accuracy. Bul.1/7.1.92

Dwg. 0/0

Derwent Class: B04; S03
International Patent Class (Main): G01N-033/53

2/34/20 (Item 9 from file: 351)

009011892
WPI Acc No: 1992-139226/ **199217**
Differential diagnosis of obstructive jaundice - involves determn. of concns. of immunoglobulin E and G in patients blood serum

Patent Assignee: ROST MED INST (ROME)
Inventor: KASUMOV E A; POLYAK A I; SHAPOSHNIK A V
Number of Countries: 001 Number of Patents: 001
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week	
SU 1649443	A	19910515	SU 4645062	A	19890213	199217	B

Priority Applications (No Type Date): SU 4645062 A 19890213
Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
SU 1649443	A		2		

Abstract (Basic): SU 1649443 A

The diagnosis comprises taking a sample of a patient's venous blood, sepg. blood serum by centrifuging and determining the content of immunoglobulin G (IgG) and E (IgE) in the serum. When the concns. of IgG and IgE increase to 4-10% and 30-38%, respectively, compared to those according to standard regulations, a benign origin of jaundice is diagnosed. An increase of IgE concn. to 500% or higher accompanied by a decrease of IgG concn. to 30-36% means that the source of jaundice is malignant.

USE/ADVANTAGE - Used in medicinal diagnosis of jaundice. The accuracy of the diagnosis is increased by 43%. Bul.18/15.5.91

Dwg. 0/0

Derwent Class: B04; S03
International Patent Class (Additional): G01N-033/53

2/34/21 (Item 10 from file: 351)

008890167
WPI Acc No: 1992-017436/199203
In-vitro detection of ring shaped particle tumour marker - by capture with anti-ring shaped particle antibody, followed by colour development techniques
Patent Assignee: AMDL INC (AMDL-N)
Inventor: GUERRERO R R
Number of Countries: 026 Number of Patents: 016
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week	
EP 465715	A	19920115	EP 90115425	A	19900810	199203	B
PT 95076	A	19920131				199210	
NO 9003537	A	19920114				199212	
AU 9060934	A	19920123				199214	
CA 2023030	A	19920114				199215	
FI 9003985	A	19920114				199215	
JP 4079899	A	19920313	JP 90228500	A	19900831	199217	
DK 9001906	A	19920114				199218	
ZA 9006540	A	19920429				199222	N
CN 1058099	A	19920122	CN 90107618	A	19900911	199239	
AU 637811	B	19930610	AU 9060934	A	19900813	199330	
IL 95354	A	19940826	IL 95354	A	19900813	199435	
JP 94098040	B2	19941207	JP 90228500	A	19900831	199502	

RU 2025734 C1 19941230 SU 4831414 A 19900910 199531
KR 9506170 B1 19950609 KR 9016416 A 19901016 199712
PH 28312 A 19940616 PH 41045 A 19900817 199838
Priority Applications (No Type Date): US 90552409 A 19900713
Cited Patents: 5.Jnl.Ref; FR 2586814; GB 2067286
Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
EP 465715	A		18		
Designated States (Regional): AT BE CH DE ES FR GB GR IT LI LU NL SE					
JP 4079899	A		14		
ZA 9006540	A		40	G01N	
AU 637811	B			G01N-033/574	Previous Publ. patent AU 9060934
JP 94098040	B2		12	C12Q-001/68	Based on patent JP 4079899
RU 2025734	C1		12	G01N-033/53	
CN 1058099	A			G01N-033/574	
IL 95354	A			G01N-033/574	
KR 9506170	B1			G01N-033/574	
PH 28312	A			G01N-033/514	

Abstract (Basic): EP 465715 A

Detecting the presence of the ring shaped particle (RSP) tumour marker in biological fluids comprises:- (a) capturing the marker in said fluid onto a substrate; and (b) detecting the presence of the marker on the substrate.

Also new is a probe that selectively binds to the marker and facilitates its detection in a biological fluid comprising:- (i) a 1st probe element to attach or associate with the tumour marker; and (ii) a probe marker linked to the 1st element.

(Ia) pref comprises attaching an anti-RSP antibody, which may be monoclonal polyclonal, affinity purified or a mixture, to the RSP marker. Alternatively a tRNA, specific to the aminoacyl transfer RNA synthetase reactive site on the marker, may be attached in the absence of Mg2+ and/or ATP.

USE/ADVANTAGE - (I) is used to detect malignancy in humans or animals. It can be used for initial diagnosis or monitoring of a tumour during treatment and for screening of potential carcinogens. RSP is a universal tumour marker so the method is widely applicable as well as being simple, quick, sensitive and of low-cost. (18pp Dwg.No.0/3

Derwent Class: B04; D16; S03
International Patent Class (Main): C12Q-001/68; G01N-033/514; G01N-033/53; G01N-033/574; G01N-233/84
International Patent Class (Additional): C07H-021/02; C07H-021/04; C07K-015/00; C12Q-031/415; G01N-033/535; G01N-033/54; G01N-033/57; G01N-033/577; G01N-033/58

2/34/9 (Item 9 from file: 345)

9867286
Basic Patent (No,Kind,Date): SU 1649443 A1 910515

PATENT FAMILY:
UNION OF THE SOVIET SOCIALIST REPUBLICS (SU)
Patent (No,Kind,Date): SU 1649443 A1 910515
METHOD FOR DIFFERENTIAL DIAGNOSTICATION OF OBSTRUCTIVE JAUNDICES (English)
Patent Assignee: ROSTOVSKIJ G MED INST (SU)
Author (Inventor): SHAPOSHNIKOV ALEKSANDR V (SU); POLYAK ALEKSANDR I (SU); KASUMOV EJNULLA A (SU); MEZHOVA LYUDMILA I (SU)
Priority (No,Kind,Date): SU 4645062 A 890213
Applic (No,Kind,Date): SU 4645062 A 890213
IPC: * G01N-033/53
Derwent WPI Acc No: ; C 92-139226
Language of Document: Russian

2/34/10 (Item 10 from file: 345)

9465254
Basic Patent (No,Kind,Date): DK 9001906 A0 19900810

PATENT FAMILY:
AUSTRALIA (AU)
Patent (No,Kind,Date): AU 9060934 A1 19920123
AN IN VITRO METHOD AND PROBE FOR DETECTING THE PRESENCE OF THE RING SHAPED PARTICLE AND MALIGNANCY IN HUMANS AND ANIMALS (English)
Patent Assignee: AMDL INC
Author (Inventor): GUERRERO ROBERT R
Priority (No,Kind,Date): US 552409 A 19900713
Applic (No,Kind,Date): AU 9060934 A 19900813
IPC: * C07H-021/02; C12Q-001/68; G01N-033/574; G01N-033/535
Language of Document: English
Patent (No,Kind,Date): AU 637811 B2 19930610
AN IN VITRO METHOD AND PROBE FOR DETECTING THE PRESENCE OF THE RING SHAPED PARTICLE AND MALIGNANCY IN HUMANS AND ANIMALS (English)
Patent Assignee: AMDL INC
Author (Inventor): GUERRERO ROBERT R
Priority (No,Kind,Date): US 552409 A 19900713
Applic (No,Kind,Date): AU 9060934 A 19900813
IPC: * C07H-021/02; C12Q-001/68; G01N-033/574; G01N-033/535
Derwent WPI Acc No: * C 92-017436
Language of Document: English
CANADA (CA)
Patent (No,Kind,Date): CA 2023030 AA 19920114
IN VITRO METHOD AND PROBE FOR DETECTING THE PRESENCE OF THE RING SHAPED PARTICLE AND MALIGNANCY IN HUMANS AND ANIMALS (English; French)
Patent Assignee: AMDL INC (US)
Author (Inventor): GUERRERO ROBERT R (US)
Priority (No,Kind,Date): US 552409 A 19900713
Applic (No,Kind,Date): CA 2023030 A 19900809
National Class: * D31670043 M
IPC: * G01N-033/574; G01N-033/567; G01N-033/577
Derwent WPI Acc No: * C 92-017436
Language of Document: English
CHINA (CN)
Patent (No,Kind,Date): CN 1058099 A 19920122
IN VITRO METHOD AND PROBE FOR DETECTING PRESENCE OF RING SHAPED

PARTICLE AND MALIGNANCY IN HUMANS AND ANIMALS (English)
Patent Assignee: AMDL INC (US)
Author (Inventor): GUERRERO ROBERT R (US)
Priority (No,Kind,Date): US 552409 A 19900713
Applic (No,Kind,Date): CN 90107618 A 19900911
IPC: * G01N-033/574; G01N-033/577
Derwent WPI Acc No: * C 92-017436
Language of Document: Chinese

DENMARK (DK)
Patent (No,Kind,Date): DK 9001906 A 19920114
FREMGANGSMAADE TIL DETEKTERING AF CANCER OG SONDE TIL BRUG VED FREMGANGSMAADEN (Danish)
Patent Assignee: AMDL INC (US)
Author (Inventor): GUERRERO ROBERT R
Priority (No,Kind,Date): US 552409 A 19900713
Applic (No,Kind,Date): DK 901906 A 19900810
IPC: * G01N-033/543; C07H-021/04; C12Q-001/68
Derwent WPI Acc No: * C 92-017436
Language of Document: Danish
Patent (No,Kind,Date): DK 9001906 A0 19900810
FREMGANGSMAADE TIL DETEKTERING AF CANCER OG SONDE TIL BRUG VED FREMGANGSMAADEN (Danish)
Patent Assignee: AMDL INC (US)
Author (Inventor): GUERRERO ROBERT R
Priority (No,Kind,Date): US 552409 A 19900713
Applic (No,Kind,Date): DK 901906 A 19900810
IPC: * G01N-033/543; C07H-021/04; C12Q-001/68
Language of Document: Danish

EUROPEAN PATENT OFFICE (EP)
Patent (No,Kind,Date): EP 465715 A1 19920115
AN IN VITRO METHOD AND PROBE FOR DETECTING THE PRESENCE OF THE RING SHAPED PARTICLE AND MALIGNANCY IN HUMANS AND ANIMALS (English; French ; German)
Patent Assignee: AMDL INC (US)
Author (Inventor): GUERRERO ROBERT R (US)
Priority (No,Kind,Date): US 552409 A 19900713
Applic (No,Kind,Date): EP 90115425 A 19900810
Designated States: (National) AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; SE
IPC: * G01N-033/574; C12Q-001/68; G01N-033/58
Derwent WPI Acc No: ; C 92-017436
Language of Document: English

FINLAND (FI)
Patent (No,Kind,Date): FI 9003985 A 19920114
ETT IN VITRO-FOERFARANDE OCH EN SOND FOER DETEKTERING AV NAERVARON AV DEN RINGFORMADE PARTIKELN OCH MALIGNITET HOS MAENSKOR OCH DJUR. (Swedish)
Patent Assignee: AMDL INC (US)
Author (Inventor): GUERRERO ROBERT R (US)
Priority (No,Kind,Date): US 552409 A 19900713
Applic (No,Kind,Date): FI 903985 A 19900813
IPC: * G01N
Language of Document: Finnish; Swedish
Patent (No,Kind,Date): FI 9003985 A0 19900813
ETT IN VITRO-FOERFARANDE OCH EN SOND FOER DETEKTERING AV NAERVARON AV DEN RINGFORMADE PARTIKELN OCH MALIGNITET HOS MAENSKOR OCH DJUR. (Swedish)
Patent Assignee: AMDL INC (US)
Author (Inventor): GUERRERO ROBERT R (US)
Priority (No,Kind,Date): US 552409 A 19900713
Applic (No,Kind,Date): FI 903985 A 19900813
IPC: * G01N
Language of Document: Finnish; Swedish

JAPAN (JP)
Patent (No,Kind,Date): JP 4079899 A2 19920313

ECTOBIOTIC METHOD AND PROBE FOR DETECTING PRESENCE OF CIRCULAR PARTICULATE AND MALIGNANT TUMOR IN HUMAN AND ANIMAL (English)
Patent Assignee: EI EMU DEII ERU INC
Author (Inventor): ROBAATO AARU GERERO
Priority (No,Kind,Date): US 552409 A 19900713
Applic (No,Kind,Date): JP 90228500 A 19900831
IPC: * C12Q-001/68; C12Q-001/42; G01N-033/574; G01N-033/577
Language of Document: Japanese
Patent (No,Kind,Date): JP 94098040 B4 19941207
Priority (No,Kind,Date): US 552409 A 19900713
Applic (No,Kind,Date): JP 90228500 A 19900831
IPC: * C12Q-001/68; G01N-033/58
Derwent WPI Acc No: * C 92-017436; C 95-365791; C 97-309882
Language of Document: Japanese

KOREA, REPUBLIC (KR)
Patent (No,Kind,Date): KR 9506170 B1 19950609
METHOD & PROBE IN VITRO FOR DETECTING THE PRESENCE OF RING SHAPED PARTICLES AND MALIGNANCY IN HUMAN & ANIMALS (English)
Patent Assignee: AMDL INC (US)
Author (Inventor): GUERRERO ROBERT R (US)
Priority (No,Kind,Date): US 552409 A 19900713
Applic (No,Kind,Date): KR 9016416 A 19901016
IPC: * G01N-033/574; C12Q-001/68
Derwent WPI Acc No: * C 92-017436
Language of Document: Korean

NORWAY (NO)
Patent (No,Kind,Date): NO 9003537 A 19920114
FREMGANGSMAATE OG PROBE FOR IN VITRO PAAVISNING AV DEN RINGFORMEDE PARTIKKEL OG KREFT HOS MENNESKER OG DYR. (Norwegian)
Patent Assignee: AMDL INC (US)
Author (Inventor): GUERRERO ROBERT R
Priority (No,Kind,Date): US 552409 A 19900713
Applic (No,Kind,Date): NO 903537 A 19900810
IPC: * G01N-033/543; G01N-033/546; G01N-033/574
Derwent WPI Acc No: * C 92-017436; C 95-365791; C 97-309882
Language of Document: Norwegian
Patent (No,Kind,Date): NO 9003537 A0 19900810
FREMGANGSMAATE OG PROBE FOR IN VITRO PAAVISNING AV DEN RINGFORMEDE PARTIKKEL OG KREFT HOS MENNESKER OG DYR. (Norwegian)
Patent Assignee: AMDL INC (US)
Author (Inventor): GUERRERO ROBERT R
Priority (No,Kind,Date): US 552409 A 19900713
Applic (No,Kind,Date): NO 903537 A 19900810
IPC: * G01N
Language of Document: Norwegian

NEW ZEALAND (NZ)
Patent (No,Kind,Date): NZ 234864 A 19920826
DETECTING RING SHAPED PARTICLES (RSP) FOR DIAGNOSING CANCER (English)
Patent Assignee: AMDL INC
Author (Inventor): GUERRERO ROBERT R
Priority (No,Kind,Date): US 552409 A 19900713
Applic (No,Kind,Date): NZ 234864 A 19900810
IPC: * G01N-033/53
Derwent WPI Acc No: * C 92-017436
Language of Document: English

PORTUGAL (PT)
Patent (No,Kind,Date): PT 95076 A 19920131
PROCESSO PARA A PREPARACAO DE COMPOSICOES PARA A DETECCAO IN VITRO DE PARTICULAS COM A FORMA ANELAR E TUMORES MALIGNOS EM SERES HUMANOS E ANIMAIS (English; French; German; Portugese)
Patent Assignee: AMDL INC (US)
Author (Inventor): GUERRERO ROBERT R (US)
Priority (No,Kind,Date): US 552409 A 19900713
Applic (No,Kind,Date): PT 95076 A 19900822
IPC: * G01N-033/53

Derwent WPI Acc No: * C 92-017436
Language of Document: Portugese
RUSSIA (RU)
Patent (No,Kind,Date): RU 2025734 C1 19941230
METHOD OF DETECTION OF TUMOR MARKER RSP IN BODY LIQUIDS, METHOD OF MALIGNANCY DETECTION, PROBE FOR SELECTIVE BINDING WITH TUMOR MARKER RSP (English)
Patent Assignee: EJ EM DI EL INK (US)
Author (Inventor): ROBERT R GERRERO (US)
Priority (No,Kind,Date): US 552409 A 19900713
Applic (No,Kind,Date): RU 4831414 A 19900910
IPC: * G01N-033/53
Derwent WPI Acc No: * C 92-017436
Language of Document: Russian
UNITED STATES OF AMERICA (US)
Patent (No,Kind,Date): US 5459035 A 19951017
METHOD OF DETECTING THE TUMORS USING RING SHAPED PARTICLES AS A TUMOR MARKER (English)
Patent Assignee: AMDL INC (US)
Author (Inventor): GUERRERO ROBERT R (US); ROUNDS DONALD E (US)
Priority (No,Kind,Date): US 987678 A 19921209; US 754272 B2 19910830; US 754273 B2 19910830; US 284688 B2 19881215; US 552409 B2 19900713
Applic (No,Kind,Date): US 987678 A 19921209
National Class: * 435006000; 435007100; 435007230; 435007940; 436503000; 436811000; 436813000; 530388800; 530388240; 530403000; 530828000; 530389100; 536023100; 935003000
IPC: * C12Q-001/68; C12Q-001/00; C07K-014/00; C07H-017/00
Derwent WPI Acc No: * C 92-017436; C 95-365791; C 97-309882; C 95-365791
Language of Document: English
Patent (No,Kind,Date): US 5635605 A 19970603
METHOD FOR DETECTING THE PRESENCE OF RING SHAPED PARTICLE TUMOR MARKER (English)
Patent Assignee: AMDL INC (US)
Author (Inventor): GUERRERO ROBERT R (US); ROUNDS DONALD E (US)
Priority (No,Kind,Date): US 398922 A 19950306; US 987678 A1 19921209; US 754272 B2 19910830; US 552409 B2 19900713; US 754273 B2 19910830; US 284688 B2 19881215
Applic (No,Kind,Date): US 398922 A 19950306
Addnl Info: 5459035 Patented
National Class: * 530412000; 530403000; 530413000; 530414000; 530415000; 530417000; 530418000; 530820000
IPC: * C07K-001/14; C07K-001/16; C07K-001/22; C07K-001/30
Derwent WPI Acc No: * C 92-017436; C 95-365791; C 97-309882; C 97-309882
Language of Document: English

2/34/22 (Item 11 from file: 351)

008717000
WPI Acc No: 1991-221019/ **199130**
Prognosis of recurrence of acute lymphoblast leukosis - using complex of specific monoclonal antibodies to detect one of several differentiating antigens
Patent Assignee: HAEMOTOLOGY BLOOD (HAEM-R)
Inventor: BULYCHEVA T I; MITEREV G Y U; NOVIKOVA M S
Number of Countries: 001 Number of Patents: 001
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week	
SU 1589215	A	19900830	SU 4311926	A	19870930	199130	B

Priority Applications (No Type Date): SU 4311926 A 19870930
Abstract (Basic): SU 1589215 A

The recurrence of acute lymphoblastic leukosis can be predicted more efficiently if a complex of specific monoclonal antibodies is used to detect one or several differentiating antigens. If such an antigen is discovered during the remission period in amounts exceeding the norm, then remission of the illness is diagnosed.

USE/ADVANTAGE - In medicine, esp. haematology. Increased accuracy of diagnosis is obtd. Bul.32/30.8.90

Dwg.0/0

Derwent Class: B04; S03
International Patent Class (Additional): G01N-033/53